SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 1, 2020
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)||(Commission File No.)||(IRS Employer Identification No.)|
|1325 Avenue of Americas, 28th Floor|
|New York, NY||10019|
|(Address of principal executive offices)||(Zip Code)|
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|o||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|o||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|o||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|o||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, $0.00005 par value||BCLI||
NASDAQ Stock Market LLC
(Nasdaq Capital Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Brainstorm Cell Therapeutics Inc. (the “Company”) appointed David Setboun as its Executive Vice President and Chief Operating Officer effective April 7, 2020.
On April 1, 2020, the Company and David Setboun entered into an employment agreement, effective as of his April 7, 2020 start date (the “Effective Date”), which sets forth the terms of Mr. Setboun’s employment (the “Agreement”). Pursuant to the Agreement, Mr. Setboun will be paid an annual salary of $400,000 (the “Base Salary”), will receive a one-time signing and relocation bonus of $40,000, and will also be eligible to receive an annual cash bonus equal to 40% of his base salary, subject to his satisfaction of pre-established performance goals to be mutually agreed upon by the Company’s CEO, the Board of Directors of the Company (the “Board”) and Mr. Setboun. Performance will be evaluated through a performance management framework and a bonus range based on the target bonus, and the bonus for 2020 will be pro-rated. During the employment period, commencing with the first anniversary of the Effective Date, Mr. Setboun will be eligible to receive an annual option to purchase 20,000 shares of common stock of the Company, $0.00005 par value (“Common Stock”) with an exercise price equal to the closing price of the common stock of the Company on the day of the grant during normal trading hours (together, the “Options”). Mr. Setboun will also receive other benefits that are generally made available to the Company’s employees.
Pursuant to the Agreement, Mr. Setboun will receive on the Effective Date, a grant of 50,000 shares of restricted stock (the “Restricted Stock”), under the Company’s 2014 Stock Incentive Plan, which shall vest as to 100% of the award on the first anniversary of the date of grant, provided Mr. Setboun remains continuously employed by the Company from the date of grant through the vesting date.
Pursuant to the Agreement, on the Effective Date, Mr. Setboun also will receive a one-time issuance of performance based restricted stock units (the “RSU”) with the following terms: upon the occurrence of specified milestones Mr. Setboun shall receive, within 10 business days, 250,000 shares of restricted Common Stock which shall vest immediately as to 100% of the award. In the event of Mr. Setboun’s termination of employment, any portion of the RSU that is not yet vested shall automatically and immediately be forfeited to the Company, without the payment of any consideration. The RSU is not subject to acceleration upon Change in Control. The milestone for the RSU is as follows: the Company had entered into a definitive commercialization agreement - prior to its phase 3 ALS trial data unblinding for its lead investigational product - with a third party that is not an affiliate or subsidiary of the Company, with respect to the Company’s primary targeted indication – Amyotrophic Lateral Sclerosis.
The Agreement contains termination provisions, pursuant to which if the Company terminates the Agreement or Mr. Setboun’s employment without Cause (as defined in the Agreement) or if Mr. Setboun terminates the Agreement or his employment thereunder with Good Reason (as defined in the Agreement), within four (4) months following a Change in Control (as defined in the Agreement), Mr. Setboun is entitled to four (4) months Base Salary in a lump sum, reimbursement of monthly COBRA premiums for four (4) months following termination, and fully accelerated vesting of all of his outstanding, unvested options or other equity instruments subject to “time-based” vesting (as opposed to “performance-based” vesting, which shall not be accelerated).
Prior to joining the Company, David Setboun served as Chief Business Officer, Corporate Development & Strategy at Life Biosciences since 2018. He also served as President France at Biogen from 2015 to 2018. He also worked for Astrazeneca as Country President (Portugal) at from 2012 to 2015, and as Sales & Marketing Director, Belgium (EU HQ) from 2009 to 2012. Mr. Setboun has also worked at Eli Lilly & Company as Cymbalta Global Marketing Director from 2002 to 2009 and at Rhone Poulenc Rorer from 1997 to 2000 as a Sales Force Effectiveness and Market Research Manager.
Mr. Setboun is 45 years old. There is no arrangement or understanding between Mr. Setboun and any other person pursuant to which he was appointed as Executive Vice President and Chief Operating Officer of the Company. There have been no transactions and are no currently proposed transactions to which the Company or any of its subsidiaries was or is a party in which Mr. Setboun has a material interest, which are required to be disclosed under Item 404(a) of Regulation S-K. There are no family relationships between Mr. Setboun and any member of the Board or other executive officer of the Company.
The above description of the Agreement is qualified in its entirety by reference to the terms of the Agreement, attached hereto as Exhibit 10.1 and incorporated herein by reference.
As of the Effective Date, Dr. Ralph Kern was appointed the Company’s President and Chief Medical Officer and ceased to serve as the Company’s Chief Operating Officer, and Chaim Lebovits ceased serving as President and continues to serve as Chief Executive Officer of the Company. There are no changes to the compensation terms of Dr. Kern or Mr. Lebovits in connection with the title changes.
Item 9.01 Financial Statements and Exhibits.
|10.1||Employment Agreement by and between Brainstorm Cell Therapeutics Inc. and David Setboun.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|BRAINSTORM CELL THERAPEUTICS INC.|
|Date: April 3, 2020||By:||
/s/ Chaim Lebovits
|Chief Executive Officer and President|
April 1, 2020
Re: Offer of Employment
Dear Mr. Setboun:
I am pleased to confirm an offer for you, by way of this offer letter (this “Letter”), to join BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation (the “Company”), on a full-time basis, in the position of Executive Vice President, Chief Operating Officer (“COO”). Your employment commencement date shall be April 7, 2020 (the “Effective Date”) and shall continue until terminated pursuant to the terms hereof (collectively, the “Employment Period”). All share numbers and share prices described herein shall be appropriately adjusted in the event of a stock split, reverse stock split, or other similar event.
The terms of your employment and compensation will consist of the following:
|(i)||Hours Commitment: You will be expected to work in a full-time capacity, meaning a 40-hour work week, with the days and hours to be mutually agreed upon by the parties, pursuant to the Company’s ordinary course of business (other than weeks that include Company recognized holidays or weeks during which you take vacation days). You shall not be permitted to have any other business activities, unless first approved in writing by the Company in its sole discretion. You may be required to travel in connection with your position. Your office shall be located at the Company’s office suite in New Jersey or Manhattan, New York. Additionally, you agree to travel to the Company’s other offices and to other destinations in connection with the provision of services by you as the Company’s COO, including as and when you are directed to do so, from time to time, by your direct supervisor.|
|(ii)||Title: Executive Vice President, Chief Operating Officer.|
|(iii)||Nature of Services: You will directly report to our Chief Executive Officer (“CEO”), and your primary responsibilities will consist of those listed on Exhibit A (collectively, the “Executive Duties”) or as may otherwise be directed from time to time by our CEO.|
|a.||In consideration of the performance of the Executive Duties, you shall be entitled to receive an annual base compensation of Four Hundred Thousand U.S. Dollars (USD$400,000.00) (the “Base Salary”), payable in installments in accordance with the general payroll practices of the Company in effect at the time such payment is made (and subject to applicable employee deductions, such as income and employment tax withholdings) during the Employment Period. No additional compensation shall be payable to you by reason of the number of hours worked or any hours worked on Saturdays, Sundays or holidays, by reason of special responsibilities assumed (whether on behalf of the Company or any of its subsidiaries or affiliates), special projects completed, or otherwise.|
|b.||You shall be eligible to receive an annual cash bonus during the Employment Period equal to up to 40% of the Base Salary, subject to your satisfaction of pre-established performance goals to be mutually agreed upon by you and the CEO and Board of Directors (the “Board”) of the Company (or a committee thereof) each year during the Employment Period. Performance shall be evaluated through a performance management framework and a bonus range based on the target bonus. Your bonus for 2020 fiscal year shall be pro-rated based on the number of days you are employed in fiscal year 2020. During the Employment Period, commencing with the first anniversary of the Effective Date, you shall be eligible to receive an annual option (the “Annual Option”) to purchase 20,000 shares of common stock of the Company with an exercise price equal to the closing price of the common stock of the Company on the day of the grant during normal trading hours according to Nasdaq, and will be categorized as an incentive stock option pursuant to Section 422 of the Internal Revenue Code to the extent you and the terms of such option qualify pursuant to the eligibility requirements (otherwise, the option grants shall be considered “non-qualified stock options”), the vesting and exercisability of which shall be subject to the satisfaction of pre-established performance goals to be determined by the Board (or a committee thereof) each year during the Employment Period. Notwithstanding the foregoing, the Annual Options are and will each be subject the limitations of the Plans and any SEC or Nasdaq listing requirements and any required Board or stockholder approvals.|
|c.||You shall be eligible to receive a one-time signing and relocation bonus of Forty Thousand ($40,000) U.S. Dollars (subject to applicable withholdings and deductions), payable within 30 days after the full execution of this Offer Letter by all parties.|
|d.||Upon the Effective Date you shall receive a one-time grant of 50,000 shares of restricted common stock of the Company (the “Restricted Stock Grant”), which shall vest as to 100% of the award on the one year anniversary of the grant date, provided you remain continuously employed by the Company from the date of grant through the vesting date. The Restricted Stock Grant shall be contingent upon your execution of one or more restricted stock agreements in such form and substance as may reasonably be determined by the Company. In the event of your termination of employment, any portion of the Restricted Stock Grant that is not yet vested shall automatically and immediately be forfeited to the Company, without the payment of any consideration to you.|
|e.||Upon the occurrence of the specified milestones as detailed in Exhibit B, you shall receive an additional one-time issuance of restricted common stock of the Company (the “Special Restricted Stock Grant”), as described on Exhibit B. The Special Restricted Stock Grant shall be contingent upon your execution of one or more restricted stock agreements in such form and substance as may reasonably be determined by the Company. In the event of your termination of employment, any portion of the Special Restricted Stock Grant that is not yet vested shall automatically and immediately be forfeited to the Company, without the payment of any consideration to you.|
|(v)||You hereby acknowledge that you are responsible for obtaining the advice of the your own tax advisors with respect to the acquisition of the Restricted Stock Grant and the Special Restricted Stock Grant, and are relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating thereto. You acknowledge that you understand that you (and not the Company) shall be responsible for your tax liability that may arise in connection with the acquisition, vesting and/or disposition of the Restricted Stock Grant and the Special Restricted Stock Grant and any accrued dividends with respect thereto. You acknowledge that you have been informed of the availability of making an election under Section 83(b) of the Internal Revenue Code, as amended, with respect to the issuance of the Restricted Stock Grant and the Special Restricted Stock Grant, and that you also are aware and understand that, as an executive officer of the Company, there will be times that you are restricted or prohibited from selling securities of the Company.|
|(vi)||In addition to the foregoing, you shall be eligible to participate in, and receive, such additional stock options or other equity awards relating to the equity of the Company as determined by the Board (or a committee thereof) in its sole and absolute discretion.|
|(vii)||Upon presentation of vouchers and similar receipts, you shall be entitled to receive reimbursement in accordance with the policies and procedures of the Company maintained from time to time for all reasonable business expenses actually incurred in the performance of the Executive Duties.|
*Subject to all mandatory withholdings required by applicable law.
|(viii)||Employee Benefits: You shall be entitled to participate in such employment benefits, including but not limited to a Section 401(k) retirement plan, health, dental, and long term disability plans as are established by the Company and as in effect from time to time applicable to executives of the Company. The Company shall provide health and dental insurance plans (at no cost to you for the premiums or other fees) or, if the Company is unable to provide such plans, the Company will reimburse you for your health and dental insurance costs. The Company shall not be required to establish, continue or maintain any other specific benefits or benefit plans other than health and dental insurance.|
|(ix)||Other Employee Benefits; Vacation: You shall be entitled to those other employee benefits which are generally offered to the Company’s full-time employees, and as required by applicable law. Notwithstanding, you shall also be entitled to vacation during each year of the Employment Period in accordance with the policies and procedures of the Company maintained from time to time; provided that you shall be entitled to 20 days of vacation per fiscal year (to be pro rated for partial years worked by you).|
|(x)||No Additional Compensation. Except as provided herein or as determined in the discretion of the Compensation Committee of the Board, you shall not be entitled to any other compensation, salary or bonuses for services as an employee of Company.|
|(xi)||Confidentiality: You will be required to execute the Company’s standard Assignment, Non-Competition, Non-Solicitation and Confidentiality Agreement on or prior to your Start Date. A copy of this Assignment, Non-Competition, Non-Solicitation and Confidentiality Agreement has been appended to this Letter for your review and execution.|
|(xii)||Termination and Consequences.|
Termination Without Cause. At any time, the Company shall have the right to terminate the Employment Period by written notice to you. Upon any termination pursuant to this Section (xii), the Company shall (i) pay to you any unpaid Base Salary through the effective date of termination specified in such notice; and (ii) pay to you the accrued and/or pro-rated but unpaid performance bonus, if any, for any period ending on or before the date of the termination of your employment with the Company, as described in the terms of your bonus arrangement (for the avoidance of doubt, any such performance bonus payment shall only be due to you if the performance targets and all conditions are fully achieved prior to the date of your employment termination). The Company shall pay to you the equivalent of four (4) months of your Base Salary in the form of salary continuation commencing on the first regularly scheduled payroll date following the effective date of the Release described in this section and reimburse you for the monthly COBRA premium paid by you for yourself and your dependents for four (4) months following the effective date of termination. The Company shall have no further liability hereunder (other than for reimbursement for reasonable business expenses incurred prior to the date of termination and consistent with the Company’s policies and procedures, subject, however, to the provisions and payment of compensation for unused vacation days that have accumulated during the calendar year in which such termination occurs). No such salary continuation or any other form of severance pay or acceleration of vesting shall be paid unless you timely execute and do not revoke a full and general waiver and release in favor of the Company, its subsidiaries, its affiliates, directors, officers, employees, shareholders, representatives and agents, as described below. Notwithstanding anything to the contrary, in no event shall the vesting for any stock options and other equity securities that are subject to “performance-based” accelerate upon or as the result of the termination of your employment for any reason.
Change in Control of the Company. (a) Payments. In the event that a termination of employment without Cause or for Good Reason occurs within four (4) months following a Change in Control (as defined in paragraph (b) of this Employment Agreement) in the Company, the Company shall pay to you the equivalent of four (4) months of Executive's Base Salary in a lump sum, reimburse you for the monthly COBRA premium paid by you for yourself and your dependents for four (4) months following the effective date of termination, and fully accelerate the vesting of all outstanding, unvested options or other equity instruments of Company Common Stock, such that all such equity shall be vested immediately and exercisable, but only such options and equity securities that are subject to “time-based” vesting (as opposed to “performance-based” vesting, which shall not be accelerated). The Company shall have no further liability hereunder (other than for reimbursement for reasonable business expenses incurred prior to the date of termination and consistent with the Company’s policies and procedures, subject, however, to the provisions of and payment of compensation for unused vacation days that have accumulated during the calendar year in which such termination occurs). (b) For purposes of this Agreement, the term “Change in Control” shall mean (i) a reorganization, merger, consolidation or other form of corporate transaction or series of transactions, in each case, with respect to which persons who were the shareholders of the Company immediately prior to such reorganization, merger or consolidation or other transaction do not, immediately thereafter, own more than 50% of the combined voting power entitled to vote generally in the election of directors of the reorganized, merged or consolidated company’s then outstanding voting securities, in substantially the same proportions as their ownership immediately prior to such reorganization, merger, consolidation or other transaction, or (ii) a liquidation or dissolution of the Company, or (iii) the sale of all or substantially all of the assets of the Company (unless such reorganization, merger, consolidation or other corporate transaction, liquidation, dissolution or sale is subsequently abandoned). No such severance payments, lump sum payments or acceleration of vesting shall occur if you fail to timely execute and do not revoke a full and general waiver and release in favor of the Company, its subsidiaries, its affiliates, directors, officers, employees, shareholders, representatives and agents, as described below.
Release and Resignation Requirement. The Severance Benefits (including all salary continuation, lump sum payments, acceleration of vesting, COBRA payments and the like) are conditional upon (i) your delivering to the Company and making effective and irrevocable a general release of all claims in favor of the Company, in a form reasonably acceptable to the Company (the “Release”), which release shall be effective seven (7) days after your signature and delivery to the Company, following the date of the applicable termination or resignation (such signature to be delivered to the Company no later than 45 days after the termination of your employment with the Company); (ii) your complying with the Release including any cooperation, non-disparagement or confidentiality provisions contained therein and continuing to comply with your obligations under the terms of this Employment Agreement, including any non-solicit and/or non-compete provisions that may be included, and the terms of the Company Protection Agreement (including Exhibit C hereof); and (iii) your resignation, to be effective no later than the date of your termination or resignation date (or such other date as reasonably requested by the Company).
|(a)||Notwithstanding any other provision of this Agreement to the contrary, you may terminate this Agreement at any time during the Employment Period, (i) for Good Reason (as defined below), or (ii) without Good Reason on (A) thirty (30) days’ prior written notice to the Company through the first anniversary of the Effective Date; or (B) sixty (60) days’ prior written notice following the first anniversary of the Effective Date.|
|(b)||Notwithstanding any other provision of this Agreement to the contrary, the Company may terminate the Employment Period upon written notice to you.|
|(d)||Subject to the other requirements of this Agreement, if either you or the Company terminates this Agreement or your employment hereunder, then (i) your Base Salary shall be discontinued upon the termination of the Agreement or your employment hereunder, (ii) no bonus compensation, accrued or otherwise, shall be payable for the year in which the termination with Cause or without Good Reason occurs, (iii) to the extent permitted by applicable law, you shall cease to be entitled to participate in any benefit plans or programs maintained by the Company, and (iv) you shall forfeit all rights to any Company unvested stock options if terminated by the Company for Cause and shall forfeit all rights with respect to any Company unvested restricted stock if terminated by the Company for Cause or if terminated by you without Good Reason. You shall be entitled to receive payment for all accrued Base Salary and benefits earned through and including the date of termination, including, but not limited to all bonus earned, but not yet paid, for the year preceding the year in which such termination occurs, payment for all accrued, unused vacation, reimbursement of all business expenses incurred through the date of termination, and all vested benefits to which the employee is entitled. In addition, you and your eligible dependents shall be entitled to continue all group health benefits at your or their expense, pursuant to applicable law.|
|(e)||If you die or are unable to perform your duties and/or any other obligations hereunder because of a Disability (as defined herein) during the term of this Agreement, then the Agreement shall terminate, except that the Company shall pay within thirty (30) days of such event all accrued Base Salary and any bonus that you would otherwise have been entitled to receive through the date that your employment with the Company is terminated. In the case of a Disability, you shall also receive any applicable payments and benefits pursuant to any disability plan or policy sponsored or maintained by the Company. The unvested Options and/or Unvested Restricted Stock Units shall remain outstanding in accordance with their existing terms and conditions.|
|(f)||“Good Reason” means (i) a material reduction of your base salary, annual bonus and or any annual equity grants and and/or benefits from the levels in effect immediately prior to the reduction, (ii) a material reduction of your duties and responsibilities from those in effect immediately prior to the reduction, or (iii) material breach by the Company of any provision of this Agreement after the Company’s receipt of written notice thereof from the you and failure by the Company to cure the breach fully within thirty (30) days (or 60 days, as described above) after the date such notice is received by the Company. A termination by you will not be considered a termination for Good Reason unless within thirty (30) days (or 60 days, as described above) of the later of the last event relied upon by you to establish Good Reason or actual knowledge thereof as demonstrated by the Company, you furnish the Company with a written statement specifying the reason or reasons why you believe you are entitled to terminate employment for Good Reason and afford the Company at least thirty (30) days (or 60 days, as described above) during which to remedy the default. Such 30 day (or 60 days, as described above) notice period may run concurrently with the 30 day notice specified in section xii a If the Company timely cures the condition giving rise to Good Reason for your resignation, the notice of termination shall become null and void. If the Company does not timely and fully cure the condition giving rise to Good Reason, your termination of employment shall be effective as of the end of such cure period, subject to the other terms of this Agreement.|
|(g)||“Cause” means a good faith finding by the Company of: (i) gross negligence or willful misconduct by you in connection with the your Executive Duties that you do not cure fully within thirty (30) days of written notice thereof by the Company to you, (ii) your indictment for, conviction of, or entry of a plea of guilty or no contest or similar plea with respect to any felony, acts of fraud, misrepresentation, embezzlement, theft, dishonesty or breach of fiduciary duty of loyalty to the Company or any of its affiliates or subsidiaries, or a material and intentional breach of any material term of this Agreement that you do not fully cure within thirty (30) days of written notice by the Company to you thereof, (iii) willful or repeated failure to follow specific directives of the CEO and/or the Board (or its committees or other designees) that are made in accordance with all applicable law and would not violate applicable law and that you do not cure fully within thirty (30) days of written notice by the Company to you thereof, (iv) willful failure or refusal to perform your Executive Duties by you (except where due to Disability or where performance of your Executive Duties is prohibited by law), which failure or refusal is not corrected by you within thirty (30) business days following receipt by you of written notice from the Company of such failure or refusal, and the actions required to correct the same, to the reasonable satisfaction of the CEO, (v) misappropriation by you of the assets or business opportunities of the Company or its affiliates or subsidiaries, (vi) any intentionally wrongful act or omission by you that has a material adverse effect on the reputation or business of the Company or any of its subsidiaries or affiliates, (vii) a willful and/or knowing breach by you of any representations or warranties included in this Agreement, or (viii) you knowingly allowing any third party to commit any of the acts described in any of the preceding clause (v) against the Company.|
|(h)||“Disability” means your inability to perform your duties pursuant to the terms of this Agreement, because of physical or mental disability where such disability shall have existed for a period of more than ninety (90) consecutive days in any two hundred seventy (270) day period. The existence of a Disability means that you cannot perform the essential functions of your position with or without reasonable accommodation. The fact of whether or not a Disability exists hereunder shall be determined by a professionally qualified medical expert reasonably chosen by you and the Company.|
|(xiii)||Special Payment Provision. Notwithstanding any provision herein to the contrary:|
|a.||This agreement is intended to comply with the requirements of Section 409A of the Code (“Section 409A”) and regulations promulgated thereunder such that no payment provided hereunder shall be subject to an “additional tax” within the meaning of Section 409A. To the extent that any provision in this agreement is ambiguous as to its compliance with Section 409A, the provision shall be read in such a manner so that all payments due under this agreement shall not be subject to any additional tax. For purposes of Section 409A, each payment made under this agreement shall be treated as a separate payment. In no event may you, directly or indirectly, designate the calendar year of payment. All reimbursements provided under this agreement shall be made or provided in accordance with the requirements of section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit.|
|b.||If payment or provision of any amount or other benefit that is a “deferral of compensation” subject to section 409A of the Code at the time otherwise specified in this agreement or elsewhere would subject such amount of benefit to additional tax pursuant to section 409A(a)(1)(B) of the Code, and if payment or provision thereof at a later date would avoid any such additional tax, then the payment or provision thereof shall be postponed to the earliest date on which such amount or benefit can be paid or provided without incurring such additional tax. In the event this Section 11(o)(ii) requires a deferral of any payment, such payment shall be accumulated and paid in a single lump sum on such earliest date together with interest for the period of delay, compounded annually, equal to the prime rate (as published in The Wall Street Journal), and in effect as of the date of the payment should otherwise have been provided.|
|c.||If any payment or benefit permitted or required under this agreement is reasonably determined by either party to be subject for any reason to a material risk of additional tax pursuant to section 409A(a)(1)(B) of the Code, then the parties shall promptly agree in good faith on appropriate provisions to avoid such risk without materially changing the economic value of this agreement to either party.|
As you are aware, you will be a full-time employee with the Company and must devote your full attention and efforts to the Company during regular work hours and your employment with the Company is "at will," which means your employment may be terminated at any time for any reason, by either party, with or without notice subject to both parties complying otherwise with the terms of this Agreement
This Agreement will be governed solely by the laws of the State of New York without giving effect to the conflict of laws principles thereof. You further agree to submit to the exclusive jurisdiction of the courts situated in the State of New York in respect of any issue and/or dispute which arises hereunder and/or in connection with your employment with the Company.
By signing this Agreement, you confirm that you are not subject to any agreements or other restrictions that would prevent you from working for the Company and carrying out the Executive Duties described herein. You further confirm that your employment with the Company will not violate or breach any confidential relationship between you and any third party, and that you will not disclose to the Company or use for the Company’s benefit any confidential or trade secret information of any third party that is not otherwise allowed by law or contract or the third party’s written consent. You agree that at no time during the period of your employment with the Company will you undertake responsibilities or obligations which will present an actual conflict of interest with, or limit your ability to reasonably fulfill the Executive Duties of your position with the Company.
You are required by law to provide documentation necessary to complete U.S. Government Form I-9. Your employment will not commence until the Company has received such materials/documentation. In addition, this offer is contingent on verification of the information you have provided on your employment application and in your job interview.
We look forward to having you join the Brainstorm team, and we are confident that you’ll contribute to its overall success. If you should have any questions please feel free to contact me at your earliest convenience.
BRAINSTORM CELL THERAPEUTICS INC.
By: /s/ Chaim Lebovits
Name: Chaim Lebovits
Title: Chief Executive Officer
ACKNOWLEDGED AND AGREED
AS OF THE DATE SET FORTH BELOW:
By: /s/ David Setboun
Name: David Setboun
Title: In his individual capacity
Chief Operating Officer Primary Responsibilities:
|·||Responsible for the company’s CMC (Chemistry, Manufacturing and Controls) or all Company’s products. Overseeing the activities of the Company’s VP Manufacturing.|
|·||Responsible for the development and successful formation of Brainstorm strategic partnerships across all geographic regions, including but not limited to: identifying strategic partnership opportunities; leading all due diligence activities; leading company negotiations; successful completion of term sheets; and management of joint venture partnerships as the Brainstorm corporate co-lead on JV committees.|
|·||Responsible for the company’s global business expansion, including: strategic partnerships; mappingח the European Union (“EU”) markets, as well as leading the company’s EU regulatory activities; identification and sourcing of non-dilutive funding opportunities; participation in Key Opinion Leader (“KOL”) engagements with other Brainstorm team members; US and EU payer and health technology assessment engagement; and sourcing appropriate EU vendors to conduct corporate activities within the EU.|
|·||Develop Brainstorm’s EU footprint and presence as necessary to support business objectives, including: establishing an EU office; developing EU manufacturing infrastructure; and hiring of Brainstorm employees or functional service providers.|
|·||Instruct, guide and supervise over the entire Commercialization efforts; Overseeing and assisting the Company’s Chief Commercial Officer. And assist the CEO, the President and the Chief Business Officer in all US NurOwn ALS launch activities as necessary.|
|·||Work collaboratively with the President and Chief Medical Officer on prioritizing and optimizing Brainstorm’s innovative cellular product portfolio across geographic regions and potential strategic partners, including: establishing research collaborations with leading academic institutions and subject matter experts; project management; program resourcing; and establishment of specific product development timelines and milestones.|
|·||Work collaboratively, under the CEO leadership, with the Chief Financial Officer and the President and the Chief Business Officer on investor and PR interactions and meetings as necessary, including: corporate reporting; investor calls; fund raising; and media interactions.|
|·||Actively contribute to the development of corporate objectives and strategic planning as part of the Brainstorm senior management team.|
Milestone for Special Restricted Stock Grant:
1. Upon occurrence of the following milestone, COO shall receive 100% of the Special Restricted Stock Grant totaling 250,000 shares of common stock of the Company which shall vest immediately as to 100% of the award. Company shall issue to you the Special Restricted Stock Grant in the appropriate amount “one time only” if and when the milestone event is achieved. Such issuance shall be made no later than ten (10) business days following achievement of the applicable milestone event. You must be employed by the Company on the date the milestone is achieved in order to receive the Special Restricted Stock Grant. The milestone for the Special Restricted Stock Grant is as follows :
|a.||The Company had entered into a definitive commercialization agreement - prior to its phase 3 ALS trial data unblinding for its lead investigational product - with a third party that is not an affiliate or subsidiary of the Company, with respect to the Company’s primary targeted indication – Amyotrophic Lateral Sclerosis.|
2. Should the COO play a material part in securing a commercialization agreement, the board of directors shall convene and discuss the option of granting COO an additional special compensation or bonus, and, in that case, the nature and scope of such compensation shall remain at the sole discretion of the board.
For purposes of this Agreement, a “commercialization agreement” shall mean any agreement signed between the Company and a third party not an affiliate or subsidiary of the Company where the purpose of this agreement is to market, launch, sell or otherwise commercialize the applicable product in any geography, and shall include, but not be limited to, the following kinds of agreements that serve the aforementioned purpose: License, Development & Commercialization Agreement; Product Commercialization Agreement; Co-Marketing Agreement; Copromotion Agreement; Contract Sales Force Agreement; Joint Venture; Product Divesture, License, Sale or Acquisition Agreement; etc.
ASSIGNMENT, NON-COMPETITION, NON-SOLICITATION
AND CONFIDENTIALITY AGREEMENT
This Assignment, Non-Competition, Non-Solicitation and Confidentiality Agreement (this “Agreement”) is hereby effective as of April 7, 2020. As a condition of my employment with BRAINSTORM CELL THERAPEUTICS INC., its subsidiaries, affiliates, successors or assigns (collectively, the "Company"), and in consideration of my employment with the Company and my receipt of the compensation now and hereinafter paid to me by the Company, I, the undersigned, agree to the following:
1. At-Will Employment. I understand and acknowledge that, unless I enter into a written employment agreement with the Company my employment with the Company is for an unspecified duration and constitutes "at-will" employment. I also understand that any representation to the contrary is unauthorized and not valid unless obtained in writing and signed by an authorized representative of the Company. I acknowledge that this employment relationship may be terminated at any time, with or without good cause or for any or no cause, at the option either of the Company or me, with or without notice.
2. Confidential Information.
2.1 Company Information. I recognize that the Company has devoted substantial money, time and resources in developing Confidential Information, and that the Company pays its employees, among other things, to develop and preserve its business information. Accordingly, I agree at all times during the term of my employment and thereafter, to hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person, firm or corporation without written authorization of an authorized representative of the Company, any Confidential Information of the Company. I understand that "Confidential Information" means any Company technology or economic competitively valuable proprietary information, technical data, patients advocacy strategies, communications relating to patients (both internal and external), trade secrets or know-how, including, but not limited to, research, product plans, company business or working plans, products, Public Relations & Investor Relation strategies or communications, pricing and pricing methods, services, customer lists and customers (including, but not limited to, prospective and actual customers of the Company on whom I called or with whom I became acquainted during the term of my employment), markets, software, developments, inventions, processes, technology, designs, drawings, models, engineering, marketing, finances, employee compensation data or other business information disclosed to me by the Company either directly or indirectly in writing, orally or by drawings or observation of parts or equipment. In addition, I agree not to do any of the following: (a) disclose or disseminate Confidential Information to anyone, including any Company employee or volunteer, who lacks a need to know; (b) remove proprietary information from the Company's premises without the express written authorization from Company; and (c) use the Confidential Information for my own or any third party's benefit. I further understand that Confidential Information does not include any of the foregoing items which have become publicly known and made generally available through no wrongful act of mine or of others who were under confidentiality obligations as to the item or items involved or improvements or new versions thereof.
2.2 Former Employer Information. I agree that I will not, during my employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former or concurrent employer or other person or entity and that I will not bring onto the premises of the Company any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity.
2.3 Third Party Information. I recognize that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out my work for the Company consistent with the Company's agreement with such third party.
2.4 Governmental Limitations. Nothing set forth in the Agreement or in any other agreement or policy of the Company shall prohibit any person from reporting possible violations of federal or state law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal or state law or regulation. No person shall require prior authorization of any party to make any such reports or disclosures, and no person shall be required to notify the Company that he or she has made such reports or disclosures. Furthermore, nothing in the Agreement shall prohibit or limit a person from receiving a whistleblower award or other financial benefit for participating in a government investigation.
3.1 Assignment of Inventions. I agree that I will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assign to the Company, or its designee, all my right, title, and interest in and to: (a) any and all inventions, developments, concepts, designs, discoveries, ideas, patents, patent applications, improvements, and all other worldwide rights of inventorship; (b) all copyrights in copyrightable works, all copyright registrations and/or applications, all original works of authorship, any derivations thereof and all moral rights appurtenant thereto; (c) all trademarks, service marks, trade names, trade dress, product names and slogans and any common law rights and good will appurtenant thereto, and all applications and registrations thereof; (d) all registered and unregistered domain names, uniform resource locators and keywords; (e) all computer and electronic data, documentation and software, including both source and object code, computer and database applications and operating programs; (f) all trade secrets and Confidential Information, including ideas, research notes, client lists, development notes, know-how, formulas, business methods and techniques and marketing, financial and pricing data; and (g) all other intellectual property rights relating to any or all of the foregoing, including any renewals, continuations or extensions thereof, whether or not patentable or registrable under copyright, trademark or similar laws (collectively hereinafter, the "Inventions"), which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time I am in the employ of the Company. I further acknowledge that all original works of authorship, as mentioned in this Section 3, which are or have been made by me (solely or jointly with others) within the scope of and during the period of my employment with the Company and which are protectible by copyright, patent and/or trademark are "works made for hire," as that term is defined in the United States Copyright Act. I understand and agree that the decision whether or not to commercialize or market any Invention developed by me solely or jointly with others is within the Company's sole discretion and for the Company's sole benefit and that no royalty will be due to me as a result of the Company's efforts to commercialize or market any such Invention.
3.2 Maintenance of Records. I agree to keep and maintain adequate and current written records of all Inventions made by me (solely or jointly with others) during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company. The records will be deemed Confidential Information and will be available to and remain the sole property of the Company at all times.
3.3 Patent, Copyright and Trademark Registrations. I agree to assist the Company, or its designee, at the Company's expense, in every proper way to secure the Company's rights in the Inventions and any copyrights, trademarks, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, trademarks, patents, mask work rights or other intellectual property rights relating thereto. I further agree that my obligation to execute or cause to be executed, when it is in my power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable because of my mental or physical incapacity or for any other reason to secure my signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as above, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patent, trademark, copyright or other intellectual property registrations thereon with the same legal force and effect as if executed by me.
4. Solicitation of Customers. I recognize that the Company pays its employees, among other things, to develop and preserve customer and client goodwill, customer loyalty and customer and client contacts for and on behalf of the Company. Accordingly, for the period of twelve (12) months after the date of termination of my employment with the Company for any reason, whether with or without cause, I will not solicit the business of any client or customer of the Company, directly or indirectly, who is such on or prior to the date of such termination. In addition, I will not solicit the business of any defined prospective client or customer. A defined prospective client or customer is one that is (a) an assigned account of any Company employee or (b) on an account list in any employee's sales or pipeline report within the last year from the termination date. I expressly agree that the limitation of this Section protects a legitimate business interest of the Company. Nevertheless, in the event that any of the restrictions and limitations contained in this Section are deemed unreasonable or to otherwise exceed the time and/or geographic limitations permitted by applicable law, such provisions of this Section shall be reformed to the maximum time and/or geographic limitations permitted by applicable law.
5. Conflicting Employment. I agree that, during the term of my employment with the Company and for a period of three (3) months after the date of termination of my employment with the Company for any reason, whether with or with cause, I will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of my employment, nor will I engage in any other activities that conflict with my obligations to the Company. I expressly agree that the limitation of this Section protects a legitimate business interest of the Company. Nevertheless, in the event that any of the restrictions and limitations contained in this Section are deemed unreasonable or to otherwise exceed the time and/or geographic limitations permitted by applicable law, such provisions of this Section shall be reformed to the maximum time and/or geographic limitations permitted by applicable law. Further, the non-competition provision in this Section shall not apply to employment and other statuses set forth in this Section in any other jurisdiction in which they are prohibited. The remainder of this Agreement shall apply within and outside of such jurisdictions.
6. Returning Company Property. I agree that, at the time of leaving the employ of the Company, I will deliver and return to the Company (and will not keep in my possession, recreate or deliver to anyone else) any and all Company-owned devices, records, data, files, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any of the aforementioned items developed by me or in my possession, including, without limitation, those records maintained pursuant to paragraph 3.3.
7. Notification of New Employer. In the event that I leave the employ of the Company, I hereby grant to the Company the right to notify my new employer about my rights and obligations under this Agreement.
8. Solicitation of Employees. I agree that for a period of twelve (12) months immediately following the termination of my relationship with the Company for any reason, whether with or without cause, I shall not either directly or indirectly solicit, induce, recruit, hire, offer employment or encourage any of the Company's employees, independent contractors or vendors to leave their employment / engagement, either for myself or for any other person or entity. I expressly agree that the limitation of this Section protects a legitimate business interest of the Company. Nevertheless, in the event that any of the restrictions and limitations contained in this Section are deemed unreasonable or to otherwise exceed the time and/or geographic limitations permitted by applicable law, such provisions of this Section shall be reformed to the maximum time and/or geographic limitations permitted by applicable law.
9. Representations. I agree to execute any proper oath or verify any proper document required to carry out the terms of this Agreement. I represent that my performance of all the terms of this Agreement will not breach any prior agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any oral or written agreement in conflict with this Agreement.
10. Equitable Relief. I acknowledge and agree that it is impossible to measure in money the damages which will accrue to the Company if I should breach or be in default of any of my representations or agreements set forth in this Agreement. Accordingly, if I breach or am in default of any such representations or agreements, the Company shall have the full right to seek injunctive relief, in addition to any other existing rights provided in this Agreement or by operation of law, without the requirement of posting bond. If any action or proceeding is instituted by or on behalf of the Company to enforce any term of this Agreement, I hereby waive any claim or defense thereto that the Company has an adequate remedy at law or that the Company has not been, or is not being, irreparably injured by my breach or default. The rights and remedies of the Company pursuant to this Section are cumulative, in addition to, and shall not be deemed to exclude, any other right or remedy which the Company may have pursuant to this Agreement or otherwise, at law or in equity.
11. Governing Law; Venue. This Agreement will be governed solely by the laws of the State of New York without giving effect to the conflict of laws principles thereof. I further agree to submit to the exclusive jurisdiction of the courts situated in the State of New York in respect of any issue and/or dispute which arises hereunder.
12. Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and supersedes all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.
13. Full Knowledge and Volition. I acknowledge and agree that I have received a copy of this Agreement, that I have read and understood all of the terms and conditions of this Agreement, and that I have had full opportunity to be advised of my right and to discuss all aspects of this Agreement with counsel of my own choosing prior to execution hereof.
14. Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect.
15. Waiver. No course of dealing or omission on the party of the Company in asserting or exercising any right, power or remedy conferred by this Agreement shall constitute or operate as a waiver thereof or otherwise prejudice its rights, powers and remedies conferred by this Agreement or shall preclude any other or further exercise thereof of any other right, power and remedy.
16. Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns.
17. Attorney’s Fees. Should I be found liable for any action taken to enforce this Agreement, I will reimburse the Company for all reasonable attorney’s fees and court costs.
18. Waiver. No act or failure to act by Company waives any rights herein. To be effective, any waiver by Company must be in writing and executed by an executive officer of the Company.
19. Headings. Section and other headings contained in this Agreement are for reference purposes only and are not intended to describe, interpret, define or limit the scope or intent of this Agreement or any provision hereof.
20. Counterparts. This Agreement may be executed in one or more counterparts each of which shall be deemed one in the same original instrument.
|BRAINSTORM CELL THERAPEUTICS INC.|
|Name: Chaim Lebovits|
|Title: Chief Executive Officer and President|
|Name: David Setboun|
|Title: In his individual capacity|